Radioligand Therapy in Lymphoma: Past, Present, and Future

Area of Science:

• Hematology
• Oncology
• Nuclear Medicine
• Immunotherapy

Background:

• Radiolabeled cells advanced hemato-oncology pathology understanding in the 1980s.
• Preclinical trials in the 1990s explored radiolabeled immunotherapy using monoclonal antibodies (MoAbs).
• Anti-CD20 agents, like Iodine-131 (Bexxar) and Yttrium-90 (Zevalin), were key developments.

Observation:

• The Food and Drug Administration approved radiolabeled MoAbs in the 2000s due to safe and durable responses.
• Despite a successful history, the clinical application of radioimmunotherapy has recently declined.
• This review examines the historical trajectory, benefits, and drawbacks of radioimmunotherapy.

Findings:

• Radioimmunotherapy offers a targeted approach to hemato-oncological diseases.
• The decline in application may stem from evolving treatment landscapes or logistical challenges.
• Future directions involve exploring novel radioligands and theranostic applications.

Implications:

• Understanding the historical context is crucial for reviving and advancing radioimmunotherapy.
• Overcoming current difficulties could re-establish radioimmunotherapy as a vital treatment modality.
• Emerging molecules may herald a new era of theranostic trends in hemato-oncology.